BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.69 USD
-0.72 (-1.01%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $70.88 +0.19 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 521 - 540 ( 822 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
One Data Set, Two Conclusions -Summary of the Drisapersen Advisory Committee Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Briefing Documents for Drisapersen Pull No Punches - But What Does it Mean?
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Growth Drivers Intact Despite Q3 Revenue Miss; DM DAdvisory Committee Next Up; Reiterate NEUTRAL and $137 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals: Potential Ripple Effect of Drisapersen''s Advisory Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Preview: We Anticipate In-Line Financials; Reiterate NEUTRAL and $137 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Merck Serono Deal Increases the Value of BioMarin''s PKU Franchise, in Our View; Reiterate NEUTRAL but Raising Price Target to $137
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L